Welcome to our dedicated page for Theralink Technologies news (Ticker: THER), a resource for investors and traders seeking the latest updates and insights on Theralink Technologies stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theralink Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theralink Technologies's position in the market.
Theralink Technologies (OTC: THER) announced a dedicated Proprietary Laboratory Analyses (PLA) code, 0249U, for its Theralink Assay for Advanced Breast Cancer. This assay measures activated protein levels, aiding oncologists in therapy selection. The company plans to bill using this new code, which may enhance its financial prospects. Additionally, Theralink is working with Medicare Administrative Contractors to establish an appropriate reimbursement rate for the Theralink test. This milestone reinforces Theralink's position as a leader in precision medicine for oncology.
Theralink Technologies (OTC: THER) announced early results of its CLIA assay for breast cancer, revealing over 90% actionability across subtypes. Analyzed from 118 patients, findings suggest oncologists change treatment plans 78% of the time using the assay. The company's patented phosphoprotein assay offers insights beyond traditional NGS tests, which typically have a 1-10% actionable rate. CEO Mick Ruxin expressed optimism about the data aiding reimbursement initiatives. Further studies and data publications are planned for 2022-2023.
Theralink Technologies has received approval for a name and ticker symbol change from 'OBMP' to 'THER,' effective February 25, 2022, as announced by FINRA. The company can now resume issuing shares of its common stock, which had been temporarily suspended. President & CEO Mick Ruxin expressed excitement about future business initiatives aimed at reducing cancer patient morbidity and mortality. Theralink Technologies specializes in precision medicine and proteomics, focusing on molecular profiling to support drug development and improve cancer outcomes.